Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry strategies

Review Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets

Obesity: Effective Treatment Requires Change in Payers\' Perspective

Roadmap to reimbursement and access

Payers Insights Into Future Oncology Management

Analysis: Drug Costs Become Bigger Issue In Cancer Care

Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet

ASCO 2010: Payer Trends in Oncology Management and Latest Clinical Trial Data

AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care Delivery Models

How Payers View Pfizer\'s Rheumatoid Arthritis Pill

Spotlight On: Delivering payer-value early in the drug development process; the role of FDA AdCom panels

New Treatment For Low Testosterone Protects Fertility

View Points: Could Pfizer\'s tofacitinib beat expectation and gain approval next month as a second-line therapy?

Looking beyond Plavix for evidence of Lipitor-type post-expiry strategies

Vbcc Aco Article

First Word Pharma View Points Commercial Prospects In The Obesity Market Physician And Analyst Observations

Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk

Payers likely to throw up hurdles to Pfizer\'s new RA drug

Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011

Tofacitinib to Be Positioned After Anti-TNFs, Say Payers Based on FDA Panel Review Reuters